Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2023

BUY
$11.55 - $20.06 $7.63 Million - $13.3 Million
660,690 New
660,690 $8.99 Million
Q1 2022

May 09, 2022

SELL
$11.55 - $20.06 $7.63 Million - $13.3 Million
-660,690 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$17.83 - $33.15 $11.8 Million - $21.9 Million
660,690 New
660,690 $13 Million
Q3 2021

Nov 14, 2022

BUY
$30.69 - $36.83 $10.1 Million - $12.1 Million
329,343 New
329,343 $10.6 Million
Q3 2021

Nov 05, 2021

SELL
$30.69 - $36.83 $10.1 Million - $12.1 Million
-329,343 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$32.66 - $39.87 $10.8 Million - $13.1 Million
329,343 New
329,343 $11.1 Million
Q2 2021

Aug 10, 2021

SELL
$32.66 - $39.87 $10.8 Million - $13.1 Million
-329,343 Closed
0 $0
Q1 2021

May 09, 2022

BUY
$33.86 - $48.68 $11.2 Million - $16 Million
329,343 New
329,343 $12.4 Million
Q1 2021

May 07, 2021

SELL
$33.86 - $48.68 $11.2 Million - $16 Million
-329,343 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$33.22 - $50.26 $10.9 Million - $16.6 Million
329,343 New
329,343 $10.9 Million
Q4 2020

Feb 10, 2021

SELL
$33.22 - $50.26 $8.62 Million - $13 Million
-259,343 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$29.24 - $40.19 $7.58 Million - $10.4 Million
259,343 New
259,343 $9.51 Million
Q3 2020

Nov 10, 2020

SELL
$29.24 - $40.19 $7.58 Million - $10.4 Million
-259,343 Closed
0 $0
Q2 2020

Aug 13, 2021

BUY
$25.06 - $54.6 $6.5 Million - $14.2 Million
259,343 New
259,343 $8.54 Million
Q2 2020

Aug 07, 2020

SELL
$25.06 - $54.6 $6.5 Million - $14.2 Million
-259,343 Closed
0 $0
Q1 2020

May 07, 2021

BUY
$24.65 - $42.83 $6.39 Million - $11.1 Million
259,343 New
259,343 $6.7 Million
Q1 2020

May 08, 2020

SELL
$24.65 - $42.83 $7.82 Million - $13.6 Million
-317,300 Closed
0 $0
Q4 2019

Mar 03, 2020

BUY
$18.59 - $37.67 $5.9 Million - $12 Million
317,300 New
317,300 $9.88 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $172M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.